Company

Vir Biotechnology, Inc.

Vir Biotechnology, Inc., founded in 2016 in San Francisco, develops antibody-based therapies for infectious diseases and cancer.

About

Vir Biotechnology, Inc. develops therapies for infectious diseases and cancer using its antibody platform and PRO-XTEN protease-releasable masking technology. Its programs focus on chronic hepatitis delta, COVID-19, and Ebola. Founded in 2016 and based in San Francisco, US, the company is led by CEO Marianne De Backer and received approximately USD 50 million in grant funding from Biomedical Advanced Research and Development Authority in October 2023. Its listed stage is Seed.

3Funding rounds

6Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in